Masonic Cancer Center, University of Minnesota: Plasmacytoma trials
The registry lists 10 Plasmacytoma studies with Masonic Cancer Center, University of Minnesota as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 5Phase 2 5No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT00612716Phase 2Results posted
- Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell TransplantTerminatedNCT00602446Phase 2Results posted
- Allogeneic Bone Marrow Transplantation Using Less Intensive TherapyTerminatedNCT00303719Phase 2Results posted
- Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantTerminatedNCT00725062Phase 1
- T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic CancerCompletedNCT00602693Phase 1
- Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesTerminatedNCT00376519Phase 1
- CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell TransplantTerminatedNCT00369291Phase 1
- Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerCompletedNCT00365287Phase 1/2
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerTerminatedNCT00290628Not applicable
- Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple MyelomaTerminatedNCT00005987Phase 2